My SciELO
Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Revista de la OFIL
On-line version ISSN 1699-714XPrint version ISSN 1131-9429
Abstract
SANZ-TAMARGO, G; MARTI-LLORCA, A; BOQUERA-FERRER, M and RAGA-BESER, A. Characteristics and results of patients admitted with COVID-19 during the pandemic. Rev. OFIL·ILAPHAR [online]. 2022, vol.32, n.4, pp.361-368. Epub Oct 23, 2023. ISSN 1699-714X. https://dx.doi.org/10.4321/s1699-714x2022000400009.
Objectives:
Describe the situation of patients and their hospital admissions due to SARS-CoV-2 infection.
Methods:
Retrospective observational study lasting more than one month (March-April) including patients admitted to a secondary hospital with a diagnosis of SARS-CoV-2 infection. The inclusion criteria were: over 18 years of age at the time of admission and diagnosis of infection by SARS-CoV-2. Demographic data and comorbidities, clinical data on admission, drugs received during ad- mission, analytical data and origin are collected.
Results:
224 patients were included. The median age was 74 years (range: 63-81) and 60.7% were men. 53.1% had more than one comorbidity. The most frequent clinical manifestations on admission were dyspnea (62.9%) and cough (62.5%), and 25% had fever. Of the treatments used, hydroxy- chloroquine and azithromycin stand out, which have been used in 91.5% and 73.2% of patients, respectively. 41.7% of the patients had lymphope- nia, and 41.1% had a D-dimer >1,000 ng/ml.
Conclusions:
Our study shows that the predominant characteristics in patients hospitalized for SARS-CoV-2 infection in our department during the early stage of the pandemic have been: men, patients over 65 years of age, with more than one comorbidity. Lymphope- nia and D-dimer elevations were the most typical laboratory abnormalities. Hydroxychloroquine and azithromycin were the two drugs that have been used the most.
Keywords : SARS-CoV-2; patients; hospital admission.